No Data
No Data
Noble Financial Maintains Tonix Pharmaceuticals(TNXP.US) With Buy Rating, Cuts Target Price to $70
Express News | Noble Capital Markets Reiterates Outperform on Tonix Pharmaceuticals, Maintains $70 Price Target
Tonix Pharmaceuticals Analyst Ratings
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
12 Health Care Stocks Moving In Wednesday's Intraday Session
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
空头包赢 : The company has not released any news, so do not listen to anyone's opinions.
job_11 : No need to worry. It's part of the normal process of the Company to get shareholders approval in advance for RS, giving them the right to exercise RS if needed within one year from shareholders approval.. As shareholders, all should vote against RS as price now is far above $1.
job_11 :